Synairgen SNG
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Synairgen shares you hold and we'll calculate your dividend payments:
Sign up for Synairgen and we'll email you the dividend information when they declare.
Add Synairgen to receive free notifications when they declare their dividends.
Your account is set up to receive Synairgen notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Synairgen dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0p | — |
| 2007 | 0.0p | 0% |
| 2008 | 0.0p | 0% |
| 2009 | 0.0p | 0% |
| 2010 | 0.0p | 0% |
| 2011 | 0.0p | 0% |
| 2012 | 0.0p | 0% |
| 2013 | 0.0p | 0% |
| 2014 | 0.0p | 0% |
| 2015 | 0.0p | 0% |
| 2016 | 0.0p | 0% |
| 2017 | 0.0p | 0% |
| 2018 | 0.0p | 0% |
| 2019 | 0.0p | 0% |
| 2020 | 0.0p | 0% |
| 2021 | 0.0p | 0% |
| 2022 | 0.0p | 0% |
| 2023 | 0.0p | 0% |
| 2024 | Sign Up Required | |
Synairgen Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 27 April 2023
- 52 Week Low
- 0.0% on 27 April 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Synairgen
Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United Kingdom
- Share Price
- £0.07 (yesterday's closing price)
- Shares in Issue
- 201 million
- Market Cap
- £13mn
- 0
- Market Indices
- none
